Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid

Nephrology

Volumn 14, Issue 2, 2009, Pages 227-234

  Lai, Ming Nan ^a,b   Lai, Jung Nien ^c   Chen, Pau Chung ^a   Tseng, Wei Lum ^c   Chen, Ya Yin ^c   Hwang, Jing Shiang ^d   Wang, Jung Der ^a,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b KUANG TIEN GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Aristolochic acid; Chinese herbal products; Chronic kidney disease

Indexed keywords

ARISTOLOCHIC ACID; CHINESE DRUG; FANGCHI; HERBACEOUS AGENT; MA DOU LING; MU TONG; MU XIANG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TIAN XIAN TENG; UNCLASSIFIED DRUG; XI XIN;

ADULT; AGED; ARISTOLOCHIA; ARTICLE; ASARUM; CHINESE HERB; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; ARISTOLOCHIC ACIDS; CHRONIC DISEASE; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 64049117979     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.01061.x     Document Type: Article

References (33)

1. Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 1998 280 : 1569 75.
2. World Health Organization. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems. Geneva : World Health Organization, 2004 Cited 9 December 2007.] Available from URL: http://www.who.int/medicinedocs/ collect/edmweb/index/assoc/s7148e/s7148e.pdf.
3. World Health Organization. General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine. Geneva 2000. Report No.: WHO/EDM/TRM/2000.1.
4. Shen-Nong-Shi The Divine Farmer's Pharmacopoeia (Herbal) Classic. Ancient medical textbook dating from the Western Han Dynasty. (In Chinese The Yellow Emperor's Classic of Medicine. Ancient medical textbook dating from the Western Han Dynasty. (In Chinese D. Understanding oriental medicine: Herbs and herbal treatment. In : Molony D (ed). The American Association of Oriental Medicine's Complete Guide to Chinese Herbal Medicine. New York : Berkley Bookshop, 1998 65 72.
5. Vanherweghem JL, Depierreux M, Tielemans C et al. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet 1993 341 : 387 91.
6. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identification of aristolochic acid in Chinese herbs [letter Lancet 1994 343 : 174.
7. Arlt VM, Stilborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis 2002 17 : 265 77.
8. Nortier JL, Martinez M-CM, Schmeiser HH et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 2000 342 : 1686 92.
9. Cosyns JP, Dehoux JP, Guiot Y et al. Chronic aristolochic acid toxicity in rabbits: A model of Chinese herbs nephropathy? Kidney Int. 2001 59 : 2164 73.
10. Kessler DA. Cancer and herbs. N. Engl. J. Med. 2000 342 : 1742 3.
11. U.S. Food & Drug Administration (FDA). Dietary Supplements: Aristolochic Acid. 2001 Cited 27 May 2005.] Available from URL: http://vm.cfsan.fda.gov/∼dms/ds-bot.html.
12. Committee on Chinese Medicine and Pharmacy, the Department of Health. Regulation of Drugs. 2003 Cited 10 Jan 2008.] http://www.ccmp.gov.tw/public/ public.asp?selno=816&relno=816&level=C (In Chinese AJ, Kasiske B, Herzog C et al. Excerpts from the United States Renal Data System 2004 annual data report: International comparisons. Am. J. Kidney Dis. 2005 45 : S217 24.
13. Taiwan Yearbook 2007, Public Health: Health Insurance. 2007 Cited 27 Jan 2008.]. Available from URL: http://www.gio.tw/taiwan%2Dwebsite/5%2Dgp/yearbook/ contents.html
14. National Health Research Institutes National Health Research Database. 2003 Cited 27 Mar 2005.] Available from URL: http://www.nhri.org.tw/resource. php.
15. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002 39 (Suppl 1 S1 266.
16. Committee on Chinese Medicine and Pharmacy, the Department of Health Unified Formulas. 2007 Cited 10 Jan 2008.] Available from URL: http://www.ccmp.gov.tw/en/information/formula.asp?relno=52&level=C.
17. Hsu YH, Tseng HH, Wen KC Determination of aristolochic acid in Fangchi radix Ann. Rept. NLFD Taiwan R.O.C. 1997 15 : 136 42 In Chinese CF, Ho YL, Tsai HY, Chong YS Studies on the commonly misused and adulterated Chinese crude drug species in Taiwan Chin Med Coll J 1999 8 : 35 46 In Chinese JS. Quality evaluation of Fang-Ji and analysis of marker constituents [dissertation]. Taiwan: Institute of Chinese Pharmaceutical Sciences, China Medical University, 2002 : 75 7.
18. Chuang MS, Hsu YH, Chang HC, Lin JH, Liao CH Studies on adulteration and misusage of marketed Akebiae caulisn Ann. Rept. NLFD Taiwan R.O.C. 2002 20 : 104 19 In Chinese AJ, Kasiske B, Herzog C et al. Excerpts from the United States Renal Data System 2004 annual data report: Chronic kidney disease, incidence & prevalence of ESRD. Am. J. Kidney Dis. 2005 45 (Suppl 1 41 70.
19. Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am. J. Kidney Dis. 2007 49 : 46 55.
20. Yang CS, Lin CH, Chang SH, Hsu HC. Rapidly progressive interstitial renal fibrosis associated Chinese herbal drug. Am. J. Kidney Dis. 2000 35 : 313 18.
21. Chang CH, Wang YM, Yang AH, Chiang SS. Rapidly progressive interstitial fibrosis associated with Chinese herbal medications. Am. J. Nephrol. 2001 21 : 441 8.
22. Chen W, Chen Y, Li A et al. The clinical and pathological manifestations of aristolochic acid nephropathy-the report of 58 cases Natl. Med. J. China 2001 81 : 1101 5 In Chinese X, Yang L, Yu Y et al. An analysis of the clinical and pathological characteristics of mu-tong (a Chinese herb) induced tubulointerstitial nephropathy.] Chin. J. Intern. Med. 2001 40 : 681 7 In Chinese SJ, Yang WC 1999 National dialysis surveillance in Taiwan Acta Nephrologica. (Taiwan Society of Nephrology) 2000 14 : 139 228 In Chinese C2003: Adult and Elderly Health Division 2003 Cited 10 Feb 2008.] Available from URL: http://www.bhp.doh.gov.tw/health91/study-2.htm (in Chinese).
23. Feest TG, Mistry CD, Grimes DS, Mallick NP. Incidence of advanced chronic renal failure and the need for end-stage renal replacement treatment. BMJ 1990 301 : 897 903.
24. Maisonneuve P. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe and Australia/New Zealand: Results from an international comparative study. Am. J. Kidney Dis. 2000 35 : 157 65.
25. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1994 331 : 1675 9.
26. Sandler DP, Smith JC, Weinberg CR et al. Analgesic use and chronic renal disease. N. Engl. J. Med. 1989 320 : 1238 43.
27. Martinez MM, Nortier J, Vereerstraeten P, Vanherweghem JL. Progression rate of Chinese herb nephropathy: Impact of Aristolochia fangchi ingested dose. Nephrol. Dial. Transplant. 2002 17 : 408 12.
28. Tanaka A, Nishida R, Maeda K, Sugawara A, Kuwahara T. Chinese herb nephropathy in Japan presents adult-onset Fanconi syndrome: Could different components of aristolochic acids cause a different type of Chineses herb nephropathy? Clin. Nephrol. 2000 53 : 301 6.
29. Lord GM, Tagore R, Cook T et al. Nephropathy caused by Chinese herbs in the UK. Lancet 1999 354 : 481 2.
30. Hsieh SC, Lai JN, Lee CF, Hu FC, Tseng WL, Wang JD. The prescribing of Chinese herbal products in Taiwan: A cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiol. Drug Saf. 2008 17 : 609 19.
31. Hashimoto K, Higuchi M, Makino B et al. Quantitive analysis of aristolochic acids, toxic compounds, contained in some medicinal plants. J. Ethnopharmacol. 1999 64 : 185 9.
32. Jong TT, Lee MR, Hsiao SS et al. Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/ atmospheric pressure chemical ionization/tandem mass spectrometry. J. Pharm. Biomed. Anal. 2003 33 : 831 7.
33. Hsu YH, Lo CF, Chang HC, Lin JH Studies on adulteration and misusage of Asari radi in the market Ann. Rept. NLFD Taiwan R.O.C. 2003 21 : 153 67 In Chinese CC, Hwang SJ, Wen CP et al. High prevalence and low awareness of CKD in Taiwan: A study on the relationship between serum creatinine and awareness from a nationally representative survey. Am. J. Kidney Dis. 2006 48 : 727 38.